Linked Life Data

12740337

Source:http://linkedlifedata.com/resource/pubmed/id/12740337

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2003-5-12
pubmed:abstractText
Previous studies in patients with osteoarthritis have suggested that the selective cyclooxygenase (COX)-2 inhibitor rofecoxib results in less gastrointestinal damage than non-selective non-steroidal antiinflammatory drugs (NSAIDs). This study compared the incidence of endoscopically detected gastroduodenal ulcers in rheumatoid arthritis patients treated with rofecoxib or a non-selective NSAID.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10096266, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10369853, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10383505, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10500058, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10511349, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10580458, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10693877, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10817549, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10871971, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10974182, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-10986213, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-11087881, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-11115219, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-11136272, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-11563999, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-1834002, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-1987872, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-299896, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-7611589, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-7698687, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-7991575, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-8121485, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-8159730, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-8328732, http://linkedlifedata.com/resource/pubmed/commentcorrection/12740337-9178711
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0017-5749
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
820-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
pubmed:affiliation
University Hospital, Nottingham, United Kingdom. cj.hawkey@nottingham.ac.uk
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Multicenter Study